tbuckley/cabot-search huggingface dataset:
Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study
Authors: Zohar Nachum, Noah Zafran, Raed Salim, Noura Hissin, Jamal Hasanein, Yifat Gam Ze Letova, Abeer Suleiman, Enav Yefet
Journal: Diabetes Care (2017)

OBJECTIVE To compare the efficacy and safety of glyburide versus metformin and their combination for the treatment of gestational diabetes mellitus (GDM). RESEARCH DESIGN AND METHODS In this prospective randomized controlled study, we randomly assigned patients with GDM at 13–33 weeks gestation and whose blood glucose was poorly controlled by diet to receive either glyburide or metformin. If optimal glycemic control was not achieved, the other drug was added. If adverse effects occurred, the drug was replaced. If both failed, insulin was given. The primary outcomes were the rate of treatment failure and glycemic control after the first-line medication according to mean daily glucose charts. RESULTS Glyburide was started in 53 patients and metformin in 51. In the glyburide group, the drug failed in 18 (34%) patients due to adverse effects (hypoglycemia) in 6 (11%) and lack of glycemic control in 12 (23%). In the metformin group, the drug failed in 15 (29%) patients, due to adverse effects (gastrointestinal) in 1 (2%) and lack of glycemic control in 14 (28%). Treatment success after second-line therapy was higher in the metformin group than in the glyburide group (13 of 15 [87%] vs. 9 of 18 [50%], respectively; P = 0.03). In the glyburide group, nine (17%) patients were eventually treated with insulin compared with two (4%) in the metformin group (P = 0.03). The combination of the drugs reduced the need for insulin from 33 (32%) to 11 (11%) patients (P = 0.0002). Mean daily blood glucose and other obstetrical and neonatal outcomes were comparable between groups, including macrosomia, neonatal hypoglycemia, and electrolyte imbalance. CONCLUSIONS Glyburide and metformin are comparable oral treatments for GDM regarding glucose control and adverse effects. Their combination demonstrates a high efficacy rate with a significantly reduced need for insulin, with a possible advantage for metformin over glyburide as first-line therapy.
Molecular Characterization of Human AML Cells with Resistance to Growth-Inhibitory and Apoptotic Effects of Hydroxamic Acid Analogue Histone Deacetylase Inhibitors.
Authors: Fei Guo, Celia Sigua, Purva Bali, Warren Fiskus, Gautam Sondarva, Srinivas Annavarapu, Abdelmoughite Mouttaki, Peter Atadja, Kapil N. Bhalla
Journal: Blood (2004)
Acute Lymphoblastic Leukemia in Children with Associated Genetic Conditions Other Than Down Syndrome. The AIEOP Experience.
Authors: Ottavio Ziino, Roberto Rondelli, Fulvio Porta, Rossella Mura, Concetta Micalizzi, Valentino Conter, Marie France Pinta Boccalatte, Chiara Messina, Matteo Luciani, Elena Barisone, Franco Locatelli, Andrea Pession, Giuseppe Basso, Andrea Biondi, Giuseppe Masera, Maurizio Aricò
Journal: Blood (2005)
Serum Levels of Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (bFGF) in Children with Acute Lymphoblastic Leukemia.
Authors: Izabela Palgan, Mariusz Wysocki, Krzysztof Palgan, Robert Debski, Grazyna Odrowaz-Sypniewska, Jan Styczynski
Journal: Blood (2004)
Clinical Activity of a Novel Multiple Tyrosine Kinase and Aurora Kinase Inhibitor, ENMD-2076, Against Multiple Myeloma: Interim Phase I Trial Results
Authors: Sherif Farag, Shuhong Zhang, Attaya Suvannasankha, Jing Liang, Robyn O'Bryant, Wood Lisa, Sushil Gupta, Mark Bray, Carolyn Fowler Sidor, Rafat Abonour
Journal: Blood (2010)
EXTH-42. PLK1 INHIBITION ENHANCES TEMOZOLOMIDE EFFICACY IN IDH1 MUTANT GLIOMAS
Authors: El Mustapha Bahassi, Robert Koncar, Zhengtao Chu, Chiaoyang Qi, Lindsey Romick-Rosendale, Susanne Wells, Timothy Chan
Journal: Neuro-Oncology (2016)

Malignant gliomas are the most frequent and lethal cancers of the central nervous system. Despite multimodal therapy with radiation and the alkylating agent temozolomide (TMZ), the disease remains incurable and ultimately fatal. Up to 90% grades II-III gliomas contain a single base substitution in one isocitrate dehydrogenase 1 (IDH1) allele. IDH1 converts isocitrate to a-ketoglutarate (aKG) while the mutant form of the enzyme converts aKG to D-2-hydroxyglutarate (D2HG). The IDH1 mutation is associated with resistance to TMZ; however, the resistance mechanism remains unclear and there is no available means of sensitizing IDH1 mutant cells to TMZ. We now show that increased resistance to TMZ is due to a G2 DNA damage checkpoint override and that this checkpoint adaptation is mediated by an increase in PLK1 activity. Importantly, we generated IDH1 mutant tumors in mice and demonstrated that the anti-tumor efficacy of BI2536 and TMZ in combination is significantly better than either drug alone as the combination treatment was able to achieve complete tumor regression. We conclude that mutant IDH1 promotes TMZ resistance and G2 checkpoint bypass with damaged DNA. Additionally, this checkpoint adaptation is facilitated by activation of PLK1, which can be exploited therapeutically with the combination of TMZ and a PLK1 inhibitor, suggesting PLK1 inhibitors may be clinically valuable in the treatment of IDH1 mutant gliomas.
Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes
Authors: L Guidugli, A K Johnson, G Alkorta-Aranburu, V Nelakuditi, K Arndt, J E Churpek, L A Godley, D Townsley, N S Young, C Fitzpatrick, D del Gaudio, S Das, Z Li
Journal: Leukemia (2017)

Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes
P08.51 Extracranial metastasis of oligodendroglioma
Authors: M. Sequeira, A. Rosinha
Journal: Neuro-Oncology (2016)

of MRI, PET and NA in terms of distinguishing stable from progressive disease in an interdisciplinary neurooncological tumour-board.RESULTS: A statistically significant and high correlation was found for all testing procedures (MRI, PET and NA) among themselves and in relation to the TB (all p>0.01).Also over time, the TB maintained the statistically significant correlation with all testing procedures (all p>0.01).NA correlated with all testing procedures significantly (TB: r=0.69,CI 0.55-0.79;MRI: r=0.35,CI 0.13-0.55;PET10: r=0.44,CI 0.23-0.61;PET60: r=0.48,CI 0.28-0.64,all p>0.01) in general.The correlations with MRI and PET increased over time, reaching a statistical significance at last FU.Consistency of test procedures increased over time.In case of inconsistent results in multimodal testing, NA and PET matched more frequently with the TB than MRI.CONCLUSION: As a novel finding, a strong correlation of NA with the TB in general and with other testing modalities during consecutive FU could be demonstrated.These results may suggest that NA is not inferior as compared to MRI and PET in terms of correlation with the TB.Whenever multimodal testing revealed inconsistent results, NA and PET were more frequently in accordance with the TB than MRI.Our data encourages further research to improve NA in multimodal response assessment.
Thromboelastometry Shows a Prothrombotic State in Systemic Lupus Erythematosus Related to Diminished Fibrinolysis and Microparticle-Derived Tissue Factor
Authors: Ihosvany Fernandez Bello, Francisco Javier López Longo, Victor Jiménez Yuste, Miguel Canales, Juan Ovalles, Nora Butta
Journal: Blood (2015)
Novel Recurrent Mutations in the Ras-Like GTP-Binding Gene Rit1 in Myeloid Malignancies
Authors: Inées Góomez-Seguíi, Hideki Makishima, Andres Jerez, Kenichi Yoshida, Bartlomiej P Przychodzen, Satoru Miyano, Yuichi Shiraishi, Holleh D Husseinzadeh, Edward P Evans, Kathryn M Guinta, Naoko Hosono, Michael A McDevitt, Alison R. Moliterno, Mikkael A. Sekeres, Seishi Ogawa, Jaroslaw P. Maciejewski
Journal: Blood (2012)
Glomerular common gamma chain confers B- and T-cell–independent protection against glomerulonephritis
Authors: Yosu Luque, Dominique Cathelin, Sophie Vandermeersch, Xiaoli Xu, Julie Sohier, Sandrine Placier, Yi-Chun Xu-Dubois, Kevin Louis, Alexandre Hertig, Jean-Christophe Bories, Florence Vasseur, Fabien Campagne, James P. Di Santo, Christian Vosshenrich, Eric Rondeau, Laurent Mesnard
Journal: Kidney International (2017)
A Novel Role for Histone Deacetylase 11 (HDAC11) in B Cell Lymphopoiesis and Plasma Cell Survival in Multiple Myeloma
Authors: Jason B. Brayer, Eva Sahakian, John Powers, Mark B Meads, Susan Deng, Allison Distler, Melissa Alsina, Taiga Nishihori, Rachid Baz, Alejandro Villagra, Javier Pinilla-Ibarz, Eduardo M. Sotomayor, Kenneth H. Shain
Journal: Blood (2014)
Acute Myeloid Leukemia Patients with Pre-Transplant Ablated Marrows Have Similar Rates of Survival and Relapse Compared to Patients in Complete Remission after Allogeneic Hematopoietic Cell Transplantation
Authors: Khoan Vu, Shivaprasad Manjappa, John F. DiPersio, Feng Gao, Peter Westervelt, Ravi Vij, Keith E. Stockerl-Goldstein, Geoffrey L. Uy, Camille N. Abboud, Mark A. Schroeder, Amanda F. Cashen, Rizwan Romee
Journal: Blood (2014)
Hyperactive Ptpn11 Mutations Alters Leukemic Stem Cell Frequency through Mcl-1 Overexpression
Authors: Lili Chen, Wei Chen, Maria Mysliwski, Justin Serio, James Ropa, Fardokht Abulwerdi, Rebecca J. Chan, Jay P. Patel, Martin S. Tallman, Elisabeth M. Paietta, Ari M Melnick, Ross L. Levine, Omar Abdel-Wahab, Zaneta Nikolovska-Coleska, Andrew G. Muntean
Journal: Blood (2014)
SNX3 Regulates Recycling of the Transferrin Receptor and Iron Assimilation in Developing Erythrocytes*
Authors: Caiyong Chen, Daniel Garcia Santos, Yuichi Ishikawa, Alexandra Seguin, Liangtao Li, Katherine H. Fegan, Gordon J. Hildick-Smith, Jeffrey D. Cooney, Wen Chen, Matthew J. King, Iman J. Schultz, Yvette Y. Yien, Arthur J. Dalton, Paul D Kingsley, James Palis, Shilpa Hattangadi, Harvey F. Lodish, Diane M. Ward, Jerry Kaplan, Takahiro Maeda, Prem Ponka, Barry H. Paw
Journal: Blood (2012)
Chemotherapy for Acute Myeloid Leukemia Can Compensate Other Adverse Prognostic Factors in Elderly: A Retrospective Longitudinal Cohort Study in a Local Community, Japan
Authors: Osamu Imataki, Hiroaki Ohnishi, Yasunori Kawachi, Makoto Ide, Makiko Uemura, Kimihiro Kawakami, Akihito Matsuoka, Masato Waki, Hidetaka Takimoto, Yasuo Hoshijima, Tetsuya Fukumoto, Kensuke Matsumoto, Fusako Waki, Teruhisa Taoka, Takuya Matsunaga
Journal: Blood (2012)
Hydroxyurea Induced Expression of Erythrocyte Anion Exchange Protein [AE1] and Gamma Globin in Cultured Erythroid Progenitor Cells.
Authors: Gloria A. Green, Beau R. Braden, Obianuju Mba, Stacy A. Chivira, Laleh Ramezani, Cage S. Johnson
Journal: Blood (2005)
C1-Inhibitor Rescues Red Blood Cells From Complement Mediated Destruction in Autoimmune Hemolytic Anemia
Authors: Diana Wouters, Stephan Femke, Masja de Haas, Conny Brouwer, Paul Strengers, Anton Hagenbeek, Marinus H.J. Van Oers, Sacha Zeerleder
Journal: Blood (2011)
CHOEP-21 Chemotherapy without Autologous Stem Cell Transplantation (ASCT) for Newly Diagnosed Nodal Peripheral T-Cell Lymphomas (PTCLs) in the Northern Part of Thailand
Authors: Ekarat Rattarittamrong, Lalita Norasetthada, Adisak Tantiworawit, Chatree Chai-adisaksopa, Weerasak Nawarawong
Journal: Blood (2012)
Comparison of Post-Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes after Matched Related Donor Versus Matched Unrelated Donor HCT in Adults with Acute Lymphoblastic Leukemia
Authors: Eric Segal, Michael Martens, Hai-Lin Wang, Ruta Brazauskas, Daniel Weisdorf, Brenda M. Sandmaier, Marcos J de Lima, H. Jean Khoury, Wael Saber
Journal: Blood (2015)
Effects of various steroid hormones on intracellular zinc uptake in prostate cancer cell lines
Authors: Dyantha Moody, Omar Bagasra, Meaghen Ashby, Naomi Kariuki, Jenica Hemingway, Frank Gooden, Andre’ Kajdacsy-Balla
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

3204 

The genetic/molecular basis of prostate cancer is unknown. The most consistent and persistent distinguishing characteristic of malignant prostate is the inability of the malignant epithelial cells to accumulate zinc. A key factor in the malignant process is the mechanism that results in this inability of the neoplastic prostate cell to accumulate zinc. hZIP1 has been identified as an important zinc uptake transporter. We have shown that gene expression of hZIP1 is downregulated in malignant cells of prostate epithelia. This project we compared the effects of varying concentrations of steroid hormones on the uptake of zinc by different prostate tissue cell lines. The intracellular zinc concentration in situ, was measured using the zinc indicator dye, Newport Green DCF, (Molecular Probes, Eugene, OR). In our studies, three steroid hormones-testosterone, β-estrodial and prolactin- at varying concentrations, ranging in concentration from .125 nM to 1.22 x 10−4 nM, and were tested on three different cell lines, each exhibiting different characteristics with regards to their dependency on various hormones. The three cell lines were: 1.) LnCAP, (ATCC # CRL-1740), an androgen-dependent epithelial prostate carcinoma isolated from the supraclavicular lymph node, 2.) PC3, (ATCC # CRL-1435), an androgen dependent epithelial prostate andenocarcinoma isolated from bone marrow tissue, and 3.) RWPE, (ATCC # CRL-2221), prostate epithelial cell line from normal tissue and transformed with HPV-18. After exposure to the three different hormones overnight, the zinc uptake of the prostate cells was assayed by utilizing zinc indicators. The intracellular levels of zinc were measured by an ELISA based reader and by microscopic visualization. Our analyses show that there is a complex interplay between various hormones with regards to zinc uptake. Implication of a potential therapy or prevention for prostate cancer utilizing a zinc supplement plus a combination of hormones will be presented.
Safety and Efficacy of High-Dose Cyclophosphamide, Etoposide, and Ranimustine (CEM) Regimen Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with High Risk De Novo Diffuse Large B-Cell Lymphoma or Diffuse Large B-Cell Lymphoma Associated with Follicular Lymphoma.
Authors: Yujin Kobayashi, Yoshihiro Hatta, Atsuko Hojo, Masaru Nakagawa, Machiko Kusuda, Yoshihito Uchino, Hiromichi Takahashi, Satomi Kiso, Yukio Hirabayashi, Mai Yagi, Hitomi Kodaira, Daisuke Kurita, Katsuhiro Miura, Noriyoshi Iriyama, Sumiko Kobayashi, Yoshimasa Kura, Akira Horikoshi, Umihiko Sawada, Masahiko Sugitani, Jin Takeuchi
Journal: Blood (2012)
CD86 and CD54 Co-Expression on VSV-G Pseudotyped HIV-1 Based Vectors Improves Transduction and Activation of Human Primary CD4+ T Lymphocytes.
Authors: Brian Paszkiet, Andrew Worden, Yajin Ni, Saran Bao, Franck Lemiale, Boro Dropulic, Laurent Humeau
Journal: Blood (2004)
Inhibitors of Heat Shock Protein 72 Induction Enhance Apoptosis Induced by Hsp90 Inhibitors
Authors: Emma Davenport, Athanasia Zeisig, Lauren Wiseglass, Hannah E. Moore, Sarah L. Hockley, David Gonzalez, Emma Smith, Swee Sharp, Paul Workman, Gareth J Morgan, Faith Davies
Journal: Blood (2008)
Myocardial Infarction With Nonobstructed Coronary Arteries
Authors: Amardeep Ghosh Dastidar, Jonathan C.L. Rodrigues, Thomas W. Johnson, Estefania De Garate, Priyanka Singhal, Anna Baritussio, Alessandra Scatteia, Julian Strange, Angus K. Nightingale, Gianni D. Angelini, Andreas Baumbach, Victoria Delgado, Chiara Bucciarelli-Ducci
Journal: JACC. Cardiovascular imaging (2017)
Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.
Authors: Jason N. Berman, Robert B. Gerbing, Lillian Sung, Kristen Miller, Jessica A. Pollard, Phoenix Ho, Derek Stirewalt, Jerald Radich, Craig A. Hurwitz, Nyla A. Heerema, Betsy Hirsch, Susana C. Raimondi, Beverly Lange, Alan S. Gamis, Janet L. Franklin, Todd A. Alonzo, Soheil Meshinchi
Journal: Blood (2009)
Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Related Transplantation in Haemoglobinopathies Leads to Early and Sustanined Engraftment with Low Incidence of VOD and GvHD
Authors: Farah O'Boyle, Sandra Hing, Yvonne Harrington, Subarna Chakravorty, Leena Karnik, Helen New, Anne Bradshaw, Richard Szydlo, Josu de la Fuente
Journal: Blood (2015)
Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Authors: Koji Sasaki, Ildefonso Ismael Rodriguez-Rivera, Hagop M. Kantarjian, Susan O'Brien, Elias Jabbour, Gautam Borthakur, Farhad Ravandi, Michael J. Burke, Patrick A. Zweidler-McKay, Jorge E. Cortes
Journal: Blood (2014)
Quality of Life Assessment in Patients Affected by Myelodysplastic Syndrome
Authors: Esther Natali e Oliva, Cristina Clissa, Valeria Santini, Antonella Poloni, Vincenzo Liso, Daniela Cilloni, Adelmo Terenzi, Stefana Impera, Alessandro Levis, Agostino Cortelezzi, Riccardo Ghio, Giampietro Semenzato, Oreste Villani, Maria Antonietta Aloe Spiriti
Journal: Blood (2008)
Cryptic NUP98/NSD1 Translocations Are Highly Prevalent in FLT3/ITD-Positive Acute Myeloid Leukemia and Lead to High Rate of Induction Failure. Report From Children's Oncology Group
Authors: Fabiana Ostronoff, Todd A. Alonzo, Robert B. Gerbing, Michael R. Loken, Laura Pardo, Richard Aplenc, Lillian Sung, Susana C. Raimondi, Betsy A. Hirsch, Samir Kahwash, Amy Heerema-McKenney, Laura Winter, Kathleen Glick, Patti Byron, Robert S. Lavey, Stella M. Davies, Franklin O. Smith, Alan S. Gamis, Soheil Meshinchi
Journal: Blood (2012)
Minimal Residual Disease Monitoring by Quantification of Fusion Gene Transcripts In Infant with MLL-rearranged Acute Lymphoblastic Leukemia Treated by MLL-Baby Protocol
Authors: Grigory Tsaur, Alexander Popov, Tatyana Nasedkina, Olga Kalennik, Anatoly Kustanovich, Olga Aleinikova, Tatyana Riger, Yulia Yakovleva, Anna Ivanova, Egor Shorikov, Leonid Saveliev, Larisa Fechina
Journal: Blood (2010)
Low Baseline Intrinsic Sensitivity to Imatinib (High IC50) in CML Patients Is Due to Reduced Oct-1 Mediated Influx. Intrinsic Sensitivity to AMN107 Does Not Correlate with That of Imatinib and Uptake of AMN107 Is Not Oct-1 Mediated.
Authors: Deborah L. White, Verity A. Saunders, Jane Engler, Phuong Dang, Andrew C.W. Zannettino, Antony Cambareri, Steven Quinn, Paul Manley, Timothy P. Hughes
Journal: Blood (2005)
The Role of Whole-Body Magnetic Resonance Imaging in the Staging and Follow-Up of Bone Disease in Multiple Myeloma.
Authors: M. Varettoni, F. Calliada, P. Zappasodi, P. Arcuti, S. Mangiacavalli, C. Rusconi, G. M. Pica, M. Lazzarino, A. Corso
Journal: Blood (2005)
Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status–Based Treatment Stratification
Authors: Bruno C. Medeiros, Holbrook E Kohrt, Richa Rajwanshi, Jason Gotlib, Steven Coutre, Michaela Liedtke, Caroline Berube, Melody Zhang, Daniel A. Arber, James L. Zehnder
Journal: Blood (2010)
Down-Regulation of<i>EPAS1</i>Transcription and Genetic Adaptation of Tibetans to High-Altitude Hypoxia
Authors: Yi Peng, Chaoying Cui, Yaoxi He, None Ouzhuluobu, Hui Zhang, Deying Yang, Qu Zhang, None Bianbazhuoma, Lixin Yang, Yibo He, Kun Xiang, Xiaoming Zhang, Sushil Bhandari, Peng Shi, None Yangla, None Dejiquzong, None Baimakangzhuo, None Duojizhuoma, Yongyue Pan, None Cirenyangji, None Baimayangji, None Gonggalanzi, Caijuan Bai, None Bianba, None Basang, None Ciwangsangbu, Shuhua Xu, Hua Chen, Shiming Liu, Tianyi Wu, Xuebin Qi, Bing Su
Journal: Molecular Biology and Evolution (2016)

Tibetans are well adapted to the hypoxic environments at high altitude, yet the molecular mechanism of this adaptation remains elusive. We reported comprehensive genetic and functional analyses of EPAS1, a gene encoding hypoxia inducible factor 2α (HIF-2α) with the strongest signal of selection in previous genome-wide scans of Tibetans. We showed that the Tibetan-enriched EPAS1 variants down-regulate expression in human umbilical endothelial cells and placentas. Heterozygous EPAS1 knockout mice display blunted physiological responses to chronic hypoxia, mirroring the situation in Tibetans. Furthermore, we found that the Tibetan version of EPAS1 is not only associated with the relatively low hemoglobin level as a polycythemia protectant, but also is associated with a low pulmonary vasoconstriction response in Tibetans. We propose that the down-regulation of EPAS1 contributes to the molecular basis of Tibetans' adaption to high-altitude hypoxia.
Prognostic Significance of High FLT3 Expression Levels in Twenty-Six MDS Patients Examined at Diagnosis and during Disease Outcome.
Authors: Paolo Bernasconi, Silvia Calatroni, Barbara Rocca, Marina Boni, Rita Zappatore, Paola Maria Cavigliano, Ilaria Giardini, Monia Lunghi, Marilena Caresana, Jessica Quarna, Carlo Castagnola, Cesare Astori, Mario Lazzarino
Journal: Blood (2005)
Donor Choice for Allogeneic Stem Cell Transplantation for AML – A Retrospective Single Centre Long-Term Analysis,
Authors: Francis Ayuk, Friedericke Bernhardt, Tatjana Zabelina, Thomas Stübig, Haefaa Alchalby, Christine Wolschke, Heinrich Lellek, Ulrike Bacher, Axel R. Zander, Nicolaus Kröger
Journal: Blood (2011)
First Clinical Report of Tipifarnib for the Treatment of T-Large Granular Lymphocyte (LGL) Leukemia.
Authors: P.K. Epling-Burnette, Lubomir Sokol, Lynn Moscinski, Magda Elkabani, Fanqi Bai, Michelle Blaskovich, JianXiang Zou, Jeffrey S. Painter, Said Sebti, Thomas P. Loughran
Journal: Blood (2007)
Effect of Repeated Apotransferrin Administrations on Serum Iron Parameters in Patients Undergoing Myeloablative Conditioning and Allogeneic Stem Cell Transplantation.
Authors: Freja Ebeling, Jaakko Parkkinen, Leila Sahlstedt, Leni von Bonsdorff, Hanna Salo, Tapani Ruutu
Journal: Blood (2006)
Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Authors: Katherine Tarlock, Todd A. Alonzo, Michael R. Loken, Robert B. Gerbing, Rhonda E. Ries, Richard Aplenc, Lillian Sung, Susana C. Raimondi, Betsy A. Hirsch, Samir B. Kahwash, Amy McKenney, E. Anders Kolb, Alan S. Gamis, Soheil Meshinchi
Journal: Clinical Cancer Research (2017)

Purpose: The FLT3 cell-surface receptor tyrosine kinase (CD135) is expressed in a majority of both acute lymphoid leukemia (ALL) and myeloid leukemia (AML). However, the prognostic significance of CD135 expression in AML remains unclear. We therefore evaluated the association between FLT3 surface expression and disease characteristics and outcomes in pediatric patients with AML.Experimental Design: We analyzed FLT3 receptor expression on AML blasts by multi-dimensional flow cytometry and its association with disease characteristics, clinical outcomes, and FLT3 transcript level in 367 children with AML treated on the Children's Oncology Group trial AAML0531.Results: There was high variability in blast CD135 cell-surface expression across specimens. CD135 expression measured by flow cytometry was not correlated with FLT3 transcript expression determined by quantitative RT-PCR. Overall, CD135 expression was not significantly different for patients with FLT3/WT, FLT3/ITD, or FLT3/ALM (P = 0.25). High cell-surface CD135 expression was associated with FAB M5 subtype (P < 0.001), KMT2A rearrangements (P = 0.009), and inversely associated with inv(16)/t(16;16) (P < 0.001). Complete remission rate, overall survival, disease-free survival, and relapse rates were not significantly different between patients with low and high CD135 expression.Conclusions: FLT3 cell-surface expression did not vary by FLT3 mutational status, but high FLT3 expression was strongly associated with KMT2A rearrangements. Our study found that there was no prognostic significance of FLT3 cell surface expression in pediatric AML. Clin Cancer Res; 23(14); 3649-56. ©2017 AACR.
MANAGEMENT OF PROCEDURAL COMPLICATIONS RELATED TO PERCUTANEOUS CORONARY INTERVENTION OF CHRONIC TOTAL OCCLUSIONS VIA THE RETROGRADE APPROACH. A TOYOHASHI EXPERIENCE
Authors: Masashi Kimura, Takahiko Suzuki, Etsuo Tsuchikane, Yoshihisa Kinoshita, Mitsuyasu Terashima, Tatsuya Ito, Maoto Habara, Nobuyoshi Tanaka, Kenya Nasu
Journal: Journal of the American College of Cardiology (2012)